Navigation Links
PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/11/2007

a Wong, M.D., Associate Professor of Pediatrics and Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, who presented the data today at CNS and is one of the trial's lead investigators. "Based on the findings from this study, we believe that the safety profile of PTC124 supports continued testing in longer-term studies."

"These results add to the growing body of safety data for PTC124, which has now been evaluated in more than 150 subjects, including patients with both DMD and cystic fibrosis. The safety profile has consistently shown that PTC124 appears well tolerated," said Langdon Miller, M.D., Chief Medical Officer of PTC. "We are looking forward to presenting additional activity data from this study next week at the World Muscle Society meeting in Italy."

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children). More information regarding DMD is available through the Muscular Dystrophy Association (http://www.mdausa.org) and the Parent Project Muscular Dystrophy (http://www.parentprojectmd.org).

About PTC124

PTC124 is an orally delivered investigational new drug in Phase 2 clinical development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely halt the translation process, producing a shortened, non- functional protein. PTC124 has restored production of full-length, functional proteins in preclinical genetic disease models harboring nonsense mutations. In Ph
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... and TORONTO , May 4, ... (OTCQB:GNBT) today announced that it intends to dividend to ... upon completion of a definitive licensing agreement to license ... ( www.smoofi.com ) (OTCQB:SMFI). As announced on ... of intent in respect of the licensing of its ...
(Date:5/4/2015)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) announced ... appointing  Donna M. Hughes, as Senior Vice President, Human ... Vice President, Chief Compliance Officer. Both Ms. Hughes and ... Executive Officer, Fred Wilkinson . "We ... Impax team," said Fred Wilkinson , President and ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3
... on complex cases, facility called ,future of hospital care, ... announces the opening of the Hamon Tower, the largest expansion ... intensive care for the region,s most critically ill patients. , ... new clinical programs for ICU patients, Hamon Tower is designed ...
... IRVINE, Calif., Oct. 2 ISTA Pharmaceuticals, Inc. (Nasdaq: ... financial results after market close on November 3, 2009. In ... p.m. Eastern Time to discuss these results and provide a ... , Time: 5:00 p.m. Eastern Time , Conference call ...
Cached Medicine Technology:Hamon Tower Features Critical Care Advances, Potential for Reduced Costs 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 During 2015-2019, ... a 7.7% CAGR. Currently, the European and APAC probiotic ... while the North American probiotic market lags behind owing ... population. , The North American probiotic market is ... 58%), followed by Canada and Mexico. The North American ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Malibu ... oral antiseptic breath spray. KissSafe™ is the first ... a safer experience while adding fresh breath appeal. ... and effectively kills germs in the mouth and ... also contains ingredients that possess additional wellness benefits. ...
(Date:5/4/2015)... 04, 2015 In a continuing effort ... substance absue, Per Wickstrom, the founder of Choices Recovery ... and the “Salute to the Oscars” celebration held ... the top floor of the luxurious Beverly Hilton Hotel. ... producer of sustainable product placement in TV and film, ...
(Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
(Date:5/4/2015)... 2015 Getting patients to work with ... is critical to achieving the “triple aim” of better ... this will require a shift in thinking from stakeholders ... health systems move beyond their traditional boundaries to reach ... the third live meeting of the ACO and ...
Breaking Medicine News(10 mins):Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4
... in collaboration with,Siemens(R), AxisThree(R), Inc. of Pacific Palisades, ... Technology into the,Plastic Surgery office of Dr. Steve ... XS-300(TM), is the first of its kind, and ... combined with,innovative proprietary software. The XS-300(TM) platform photographs ...
... launch of its redesigned web site at www.oci.com , ... ... to meet the needs of its customers and target market, OCI is ... The site features improved content, an enhanced look and feel, and easy ...
... percent savings on medical services and healthcare products. , ... ... -- Allsup announced today it is offering a new http://www.allsup.com/Health-Discount-Program.aspx/?=PRJ2 ... of people with disabilities gain access to discounted healthcare and ...
... prescription drug samples distributed to children may be unsafe, ... Alliance and Hasbro Children,s Hospital. The national study, the ... children, appears in the October 2008 issue of ... as researchers at Harvard Medical School and the Warren ...
... long way toward helping severely obese individuals improve their ... to researchers at the Duke Diet and Fitness Center. ... average, just under one hour of exercise per week, ... life. They also reported improvements in their ability to ...
... Extendicare Skilled Nursing Facilities Named In Wash. Lawsuit, ... with,additional allegations in the class action lawsuit against ... the state of Washington [see,list by city at ... in,United States District Court, Western Washington Division, in ...
Cached Medicine News:Health News:Plan Your Breasts in 3-D 2Health News:Information Management Solutions Provider OCI Announces Redesign of Corporate Web Site 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3Health News:Free drug samples carry risks for children 2Health News:A little exercise goes a long way for severely obese 2Health News:Additional Allegations Filed Against Elder Care Operator 2Health News:Additional Allegations Filed Against Elder Care Operator 3Health News:Additional Allegations Filed Against Elder Care Operator 4Health News:Additional Allegations Filed Against Elder Care Operator 5
... the only in-office test approved by the FDA ... BladderChek Test is a painless and non-invasive assay, ... elevated levels of NMP22 protein. Healthy individuals generally ... the urine. However, the level of NMP22 protein ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for suprapubic monitoring of bladder pressures. Suprapubic urodynamic studies avoid the effects of urethral catheterization and eliminate the need for a double bladder puncture. Supplied sterile...
... point-of-care (POC) diagnosis of patients with acute ... embolism. For use in doctors offices or ... counts, the Cardiac reader analyzer allows the ... D-Dimer from a single whole blood sample ...
Medicine Products: